5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week

The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index jumped 30.2% in November, on average, and were up a further 2.8% last week but remain down 10.1% YTD, on average.

Below is how they performed, in descending order, with pertinent news.

  1. Atai Life Sciences (ATAI): up 16.3%
  2. Compass Pathways (CMPS): up 8.2%
  3. Incannex Healthcare (IXHL): up 5.7%
  4. Mind Medicine (MNMD): down 2.7%
  5. GH Research (GHRS): down 4.2%
    • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
    • Read: GH Research Stock Forecast & Price Target


Summary

The munKNEE Psychedelic Drug Stocks Index was down 14.3% in August, down another 14.2% in September and down 27.3% in October but was up 30.2% in November and was up another 2.8% last week but is still down 10.1% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, was up 2.3% and remains down 28.5% YTD.


More By This Author:

5 Largest Cannabis (Marijuana) LP Stocks Up 9% This Week
A Managed Futures ETF For Investing In Bitcoin
Silver Update: 73% Of Analysts Have Already Seen Their Targets For 2023 Surpassed

Disclosure:

None

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample here).

STOCKS IN THIS ARTICLE

Comments